Artificial intelligence enhances whole‐slide interpretation of PD‐L1 CPS in triple‐negative breast cancer: A multi‐institutional ring study
Histopathology · 2024
DOI: 10.1111/his.15205 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Histopathology, 2024. Verfasst von Jinze Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, B7-H1 Antigen, Artificial Intelligence. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: 2022 Hebei Provincial Department of Finance-Government funded Clinical Medicine Excellent Talents Project.
Abstract (Originalsprache)
Background and aims Evaluation of the programmed cell death ligand‐1 (PD‐L1) combined positive score (CPS) is vital to predict the efficacy of the immunotherapy in triple‐negative breast cancer (TNBC), but pathologists show substantial variability in the consistency and accuracy of the interpretation. It is of great importance to establish an objective and effective method which is highly repeatable.
Methods
We proposed a model in a deep learning‐based framework, which at the patch level incorporated cell analysis and tissue region analysis, followed by the whole‐slide level fusion of patch results. Three rounds of ring studies (RSs) were conducted. Twenty‐one pathologists of different levels from four institutions evaluated the PD‐L1 CPS in TNBC specimens as continuous scores by visual assessment and our artificial intelligence (AI)‐assisted method.
Results
In the visual assessment, the interpretation results of PD‐L1 (Dako 22C3) CPS by different levels of pathologists have significant differences and showed weak consistency. Using AI‐assisted interpretation, there were no significant differences between all pathologists ( P = 0.43), and the intraclass correlation coefficient (ICC) value was increased from 0.618 [95% confidence interval (CI) = 0.524–0.719] to 0.931 (95% CI = 0.902–0.955). The accuracy of interpretation result is further improved to 0.919 (95% CI = 0.886–0.947). Acceptance of AI results by junior pathologists was the highest among all levels, and 80% of the AI results were accepted overall.
Conclusion
With the help of the AI‐assisted diagnostic method, different levels of pathologists achieved excellent consistency and repeatability in the interpretation of PD‐L1 (Dako 22C3) CPS. Our AI‐assisted diagnostic approach was proved to strengthen the consistency and repeatability in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- AI Lab, Tencent, Shenzhen, Guangdong, China.
ORCID-Profile: Pei Dong, Xiao Han, Yueping Liu
Förderung
- 2022 Hebei Provincial Department of Finance-Government funded Clinical Medicine Excellent Talents Project
Zitieren
APA
Li, J., Dong, P., Wang, X., Zhang, J., Zhao, M., Shen, H., Cai, L., He, J., Han, M., Miao, J., Liu, H., Yang, W., Han, X., & Liu, Y. (2024). Artificial intelligence enhances whole‐slide interpretation of PD‐L1 CPS in triple‐negative breast cancer: A multi‐institutional ring study. Histopathology. https://doi.org/10.1111/his.15205
Vancouver
Li J, Dong P, Wang X, Zhang J, Zhao M, Shen H, et al. Artificial intelligence enhances whole‐slide interpretation of PD‐L1 CPS in triple‐negative breast cancer: A multi‐institutional ring study. Histopathology. 2024. doi:10.1111/his.15205
BibTeX
@article{Li2024,
author = {Li, Jinze and Dong, Pei and Wang, Xinran and Zhang, Jun and Zhao, Meng and Shen, Haocheng and Cai, Lijing and He, Jiankun and Han, Mengxue and Miao, Jiaxian and Liu, Hongbo and Yang, Wei and Han, Xiao and Liu, Yueping},
title = {Artificial intelligence enhances whole‐slide interpretation of PD‐L1 CPS in triple‐negative breast cancer: A multi‐institutional ring study},
journal = {Histopathology},
year = {2024},
doi = {10.1111/his.15205}
}
EUVIMED